Published in Front Endocrinol (Lausanne) on February 22, 2017
On the origin of cancer cells. Science (1956) 49.55
Autophagy in the pathogenesis of disease. Cell (2008) 34.68
Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med (2007) 33.21
Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med (2006) 19.09
Overweight, obesity and cancer: epidemiological evidence and proposed mechanisms. Nat Rev Cancer (2004) 16.69
AMPK and mTOR regulate autophagy through direct phosphorylation of Ulk1. Nat Cell Biol (2011) 15.71
An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor gamma (PPAR gamma). J Biol Chem (1995) 13.34
Activation of a member of the steroid hormone receptor superfamily by peroxisome proliferators. Nature (1990) 11.92
Insulin and insulin-like growth factor signalling in neoplasia. Nat Rev Cancer (2008) 11.50
Inhibition of adipogenesis by Wnt signaling. Science (2000) 9.72
Thiazolidinediones. N Engl J Med (2004) 9.42
FoxO3 controls autophagy in skeletal muscle in vivo. Cell Metab (2007) 8.90
Eaten alive: a history of macroautophagy. Nat Cell Biol (2010) 8.83
Targeted disruption of the alpha isoform of the peroxisome proliferator-activated receptor gene in mice results in abolishment of the pleiotropic effects of peroxisome proliferators. Mol Cell Biol (1995) 7.12
The mechanisms of action of PPARs. Annu Rev Med (2002) 6.71
Insulin-like growth factors and neoplasia. Nat Rev Cancer (2004) 6.29
Adipocytes promote ovarian cancer metastasis and provide energy for rapid tumor growth. Nat Med (2011) 6.15
Autophagy: dual roles in life and death? Nat Rev Mol Cell Biol (2005) 5.80
Risk of bladder cancer among diabetic patients treated with pioglitazone: interim report of a longitudinal cohort study. Diabetes Care (2011) 5.63
Autophagy and signaling: their role in cell survival and cell death. Cell Death Differ (2005) 5.40
The PPARs: from orphan receptors to drug discovery. J Med Chem (2000) 5.29
Diabetes mellitus as a predictor of cancer mortality in a large cohort of US adults. Am J Epidemiol (2004) 5.29
Improvement in glucose tolerance and insulin resistance in obese subjects treated with troglitazone. N Engl J Med (1994) 5.28
Differentiation and reversal of malignant changes in colon cancer through PPARgamma. Nat Med (1998) 5.16
Diabetes and cancer. Endocr Relat Cancer (2009) 5.04
Control of the peroxisomal beta-oxidation pathway by a novel family of nuclear hormone receptors. Cell (1992) 4.95
Antidiabetic therapies affect risk of pancreatic cancer. Gastroenterology (2009) 4.72
Obesity and the role of adipose tissue in inflammation and metabolism. Am J Clin Nutr (2006) 4.72
The reverse Warburg effect: aerobic glycolysis in cancer associated fibroblasts and the tumor stroma. Cell Cycle (2009) 4.69
Muscle-specific Pparg deletion causes insulin resistance. Nat Med (2003) 3.93
Liver peroxisome proliferator-activated receptor gamma contributes to hepatic steatosis, triglyceride clearance, and regulation of body fat mass. J Biol Chem (2003) 3.90
Troglitazone increases the number of small adipocytes without the change of white adipose tissue mass in obese Zucker rats. J Clin Invest (1998) 3.76
Insulin receptor isoforms and insulin receptor/insulin-like growth factor receptor hybrids in physiology and disease. Endocr Rev (2009) 3.53
Autophagy: basic principles and relevance to disease. Annu Rev Pathol (2008) 3.52
Insulin receptor isoform A, a newly recognized, high-affinity insulin-like growth factor II receptor in fetal and cancer cells. Mol Cell Biol (1999) 3.50
Ligands for peroxisome proliferator-activated receptorgamma and retinoic acid receptor inhibit growth and induce apoptosis of human breast cancer cells in vitro and in BNX mice. Proc Natl Acad Sci U S A (1998) 3.46
Thiazolidinediones and the risk of lung, prostate, and colon cancer in patients with diabetes. J Clin Oncol (2007) 3.39
Thiazolidinediones in the treatment of insulin resistance and type II diabetes. Diabetes (1996) 3.21
Transcriptional activation by peroxisome proliferator-activated receptor gamma is inhibited by phosphorylation at a consensus mitogen-activated protein kinase site. J Biol Chem (1997) 3.19
Obesity and cancer. Oncogene (2004) 3.01
Peroxisome-proliferator-activated receptors and cancers: complex stories. Nat Rev Cancer (2004) 2.93
PPARs: therapeutic targets for metabolic disease. Trends Pharmacol Sci (2005) 2.90
Cancer-associated adipocytes exhibit an activated phenotype and contribute to breast cancer invasion. Cancer Res (2011) 2.85
Ligand for peroxisome proliferator-activated receptor gamma (troglitazone) has potent antitumor effect against human prostate cancer both in vitro and in vivo. Cancer Res (1998) 2.67
The metabolic syndrome: A high-risk state for cancer? Am J Pathol (2006) 2.46
Erosion of the chronic myeloid leukaemia stem cell pool by PPARγ agonists. Nature (2015) 2.45
PPARgamma ligands inhibit primary tumor growth and metastasis by inhibiting angiogenesis. J Clin Invest (2002) 2.31
Regulation of peroxisome proliferator-activated receptor gamma activity by mitogen-activated protein kinase. J Biol Chem (1997) 2.31
Cyclin D1 induction in breast cancer cells shortens G1 and is sufficient for cells arrested in G1 to complete the cell cycle. Proc Natl Acad Sci U S A (1994) 2.29
Insulin and IGF-1 stimulate the beta-catenin pathway through two signalling cascades involving GSK-3beta inhibition and Ras activation. Oncogene (2001) 2.25
Effects of ligand activation of peroxisome proliferator-activated receptor gamma in human prostate cancer. Proc Natl Acad Sci U S A (2000) 2.23
Peroxisome proliferator-activated receptor gamma ligands are potent inhibitors of angiogenesis in vitro and in vivo. J Biol Chem (1999) 2.13
PPARalpha: energy combustion, hypolipidemia, inflammation and cancer. Nucl Recept Signal (2010) 2.08
An autopsy case of troglitazone-induced fulminant hepatitis. Diabetes Care (1998) 2.08
Functional interaction between peroxisome proliferator-activated receptor gamma and beta-catenin. Mol Cell Biol (2006) 1.95
Hepatic autophagy is suppressed in the presence of insulin resistance and hyperinsulinemia: inhibition of FoxO1-dependent expression of key autophagy genes by insulin. J Biol Chem (2009) 1.93
Effects of rosiglitazone and metformin on liver fat content, hepatic insulin resistance, insulin clearance, and gene expression in adipose tissue in patients with type 2 diabetes. Diabetes (2004) 1.92
Metabolic effects of new oral hypoglycemic agent CS-045 in NIDDM subjects. Diabetes Care (1992) 1.92
Characterization of new oral antidiabetic agent CS-045. Studies in KK and ob/ob mice and Zucker fatty rats. Diabetes (1988) 1.86
Thiazolidinediones and PPARγ agonists: time for a reassessment. Trends Endocrinol Metab (2012) 1.86
Adipose tissue and adipocytes support tumorigenesis and metastasis. Biochim Biophys Acta (2013) 1.85
Insulin-like growth factor 1 regulates the location, stability, and transcriptional activity of beta-catenin. Proc Natl Acad Sci U S A (2000) 1.83
Tumor suppressor and anti-inflammatory actions of PPARgamma agonists are mediated via upregulation of PTEN. Curr Biol (2001) 1.83
Growth-promoting interaction of IGF-II with the insulin receptor during mouse embryonic development. Dev Biol (1997) 1.80
PPARalpha agonist fenofibrate suppresses tumor growth through direct and indirect angiogenesis inhibition. Proc Natl Acad Sci U S A (2008) 1.80
Insulin receptor isoforms and insulin-like growth factor receptor in human follicular cell precursors from papillary thyroid cancer and normal thyroid. J Clin Endocrinol Metab (2010) 1.79
Oleoylethanolamide stimulates lipolysis by activating the nuclear receptor peroxisome proliferator-activated receptor alpha (PPAR-alpha). J Biol Chem (2004) 1.73
Ligands for peroxisome proliferator-activated receptor gamma inhibit growth and induce apoptosis of human papillary thyroid carcinoma cells. J Clin Endocrinol Metab (2001) 1.65
Peroxisome proliferator-activated receptor gamma induces growth arrest and differentiation markers of human colon cancer cells. Jpn J Cancer Res (1999) 1.63
Interaction with MEK causes nuclear export and downregulation of peroxisome proliferator-activated receptor gamma. Mol Cell Biol (2006) 1.59
Rosiglitazone suppresses human lung carcinoma cell growth through PPARgamma-dependent and PPARgamma-independent signal pathways. Mol Cancer Ther (2006) 1.57
Mature adipocytes, but not preadipocytes, promote the growth of breast carcinoma cells in collagen gel matrix culture through cancer-stromal cell interactions. J Pathol (2003) 1.56
Insulin resistance and cancer risk: an overview of the pathogenetic mechanisms. Exp Diabetes Res (2012) 1.55
Insulin receptor and cancer. Endocr Relat Cancer (2011) 1.52
Inhibition of human lung cancer cell growth by the peroxisome proliferator-activated receptor-gamma agonists through induction of apoptosis. Biochem Biophys Res Commun (2000) 1.52
Peroxisome proliferator-activated receptor-gamma activation inhibits tumor progression in non-small-cell lung cancer. Oncogene (2004) 1.50
Cancer risks in thiazolidinedione users compared to other anti-diabetic agents. Pharmacoepidemiol Drug Saf (2007) 1.50
Peroxisome proliferator-activated receptor alpha activation decreases metastatic potential of melanoma cells in vitro via down-regulation of Akt. Clin Cancer Res (2006) 1.49
Overexpression of GRP78 and GRP94 are markers for aggressive behavior and poor prognosis in gastric carcinomas. Hum Pathol (2008) 1.49
Novel sequence determinants in peroxisome proliferator signaling. J Biol Chem (1995) 1.48
The IRE1α/XBP1s Pathway Is Essential for the Glucose Response and Protection of β Cells. PLoS Biol (2015) 1.47
Insulin- and mitogen-activated protein kinase-mediated phosphorylation and activation of peroxisome proliferator-activated receptor gamma. J Biol Chem (1996) 1.46
Novel high-affinity PPARgamma agonist alone and in combination with paclitaxel inhibits human anaplastic thyroid carcinoma tumor growth via p21WAF1/CIP1. Oncogene (2006) 1.45
A novel autocrine loop involving IGF-II and the insulin receptor isoform-A stimulates growth of thyroid cancer. J Clin Endocrinol Metab (2002) 1.44
The role of insulin receptor isoforms and hybrid insulin/IGF-I receptors in human cancer. Curr Pharm Des (2007) 1.43
Peroxisome proliferator-activated receptor gamma regulates E-cadherin expression and inhibits growth and invasion of prostate cancer. Mol Cell Biol (2006) 1.37
Rosiglitazone and risk of cancer: a meta-analysis of randomized clinical trials. Diabetes Care (2008) 1.33
Autophagy in human tumors: cell survival or death? Cell Death Differ (2004) 1.33
Repression of beta-catenin function in malignant cells by nonsteroidal antiinflammatory drugs. Proc Natl Acad Sci U S A (2005) 1.32
High-level IGF1R expression is required for leukemia-initiating cell activity in T-ALL and is supported by Notch signaling. J Exp Med (2011) 1.31
PPARgamma insufficiency promotes follicular thyroid carcinogenesis via activation of the nuclear factor-kappaB signaling pathway. Oncogene (2006) 1.28
Effect of new oral antidiabetic agent CS-045 on glucose tolerance and insulin secretion in patients with NIDDM. Diabetes Care (1991) 1.28
Activation of peroxisome proliferator-activated receptor gamma by troglitazone inhibits cell growth through the increase of p27KiP1 in human. Pancreatic carcinoma cells. Cancer Res (2000) 1.27
Metabolic syndrome and cancer. Metab Syndr Relat Disord (2009) 1.24
Resveratrol suppresses IGF-1 induced human colon cancer cell proliferation and elevates apoptosis via suppression of IGF-1R/Wnt and activation of p53 signaling pathways. BMC Cancer (2010) 1.24
Human and rat peroxisome proliferator activated receptors (PPARs) demonstrate similar tissue distribution but different responsiveness to PPAR activators. J Steroid Biochem Mol Biol (1994) 1.24
Peroxisomal proliferator-activated receptor-gamma agonists induce partial reversion of epithelial-mesenchymal transition in anaplastic thyroid cancer cells. Endocrinology (2006) 1.23
PPARs and their metabolic modulation: new mechanisms for transcriptional regulation? J Intern Med (2007) 1.21
The Molecular Chaperone GRP78/BiP in the Development of Chemoresistance: Mechanism and Possible Treatment. Front Pharmacol (2013) 1.18
The emerging role of insulin and insulin-like growth factor signaling in cancer stem cells. Front Endocrinol (Lausanne) (2014) 1.04
New insights on the Intrinsic, Pro-Apoptotic Effect of IGFB3 in Breast Cancer. Front Endocrinol (Lausanne) (2014) 0.75